Can a common sedative stop ICU delirium in heavy drinkers?
NCT ID NCT07428681
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving lorazepam, a sedative, can prevent delirium in intensive care patients who are at high risk due to heavy alcohol use. Researchers will use a blood test (Anttila-Index) to identify these patients. The trial involves 260 adults admitted to the ICU, who will receive either lorazepam or a placebo every 6 hours for 3 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lorazepam
What this could lead to
If it works, this could provide a simple way to prevent delirium in ICU patients with a history of heavy drinking, potentially reducing complications and hospital stays.
What could go wrong
This is a single-center trial with 260 participants, so results may not apply broadly. Lorazepam is a sedative and could cause side effects like drowsiness or dependence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DELIRIUM CONFUSIONAL STATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••